Open AccessTc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer
Author(s) -
Kanhaiyalal Agrawal,
P. Sai Sradha Patro,
Chappity Preetam
Publication year - 2019
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr-2018-227910
Subject(s) - medicine , nuclear medicine , octreotide , somatostatin receptor , positron emission tomography , thyroglobulin , emission computed tomography , scintigraphy , radionuclide therapy , thyroid cancer , single photon emission computed tomography , thyroid , radiology , somatostatin
There is literature evidence showing utility of somatostatin receptor (SSTR) positron emission tomography-CT (PET-CT) imaging in differentiated thyroid cancer with Thyroglobulin Elevated and Negative Iodine Scan (TENIS). These patients are less benefited with I-131 therapy and surgery remains only curable option if disease could be localised. If surgery is not feasible, other therapeutic options are not promising. However, if these patients show strongly positive SSTR imaging, then possibility of peptide receptor radionuclide therapy may be explored. As SSTR PET-CT imaging is expensive and not widely available, Technetium-99m (Tc-99m) hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC), which is a Single photon emission computed tomography (SPECT) tracer, can be used. We are documenting a case of raised serum thyroglobulin antibody and negative I-131 whole body scan with disease recurrence localised on Tc-99m HYNIC-TOC scan.